These companies are on track to soon file for U.S. emergency use authorization (EUA). And their chances of winning EUA appear to be quite good. Both BNT162b2 and mRNA-1273 could become available to the first wave of Americans by the end of the year.
While Pfizer and Moderna are the leaders now, that doesn't mean they'll maintain the position indefinitely. Here's the coronavirus vaccine maker that's most likely to blow past both of these drugmakers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,